NHS Dudley Health Economy Medicines Formulary
Home > 11 Eye > 11.8 Miscellaneous ophthalmic preparations > 11.8.2 Ocular diagnostic and peri-operative preparations and photodynamic treatment > Macular oedema (diabetic) - ranibizumab - NICE TAG TA274

Macular oedema (diabetic) - ranibizumab - NICE TAG TA274

1.1 Ranibizumab is recommended as an option for treating visual impairment due to diabetic macular oedema only if:

  • the eye has a central retinal thickness of 400 micrometres or more at the start of treatment and

  • the manufacturer provides ranibizumab with the discount agreed in the patient access scheme revised in the context of this appraisal.

1.2 People currently receiving ranibizumab for treating visual impairment due to diabetic macular oedema whose disease does not meet the criteria in 1.1 should be able to continue treatment until they and their clinician consider it appropriate to stop.

 

http://www.nice.org.uk/guidance/TA274

Site by Devopa
© Copyright 2019 NHS. All rights reserved.